

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/733,865
Filing Date	December 8, 2000
First Named Inventor	Schraa et al.
Group Art Unit	1632
Examiner Name	Q. Li
Attorney Docket Number	2578-4257 IUS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>[Signature]</i>		BENIHOUD et al., "Adenovirus vectors for gene delivery," Current Opinion in Biotechnology, October 1999 pp. 440-47, Vol. 10, no. 5.	
<i>[Signature]</i>		BRAMSON, et al., "Pre-existing immunity to adenovirus does not prevnt tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination," Gene Therapy, pp. 1069-76, Vol. 4, no. 10.	
<i>[Signature]</i>		HARVEY et al., "Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs." Journal of Virology, August 1999, pp. 6729-42, Vol. 73, no. 8.	
<i>[Signature]</i>		MURUVE, et al., "Adenivoral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo," Human Gene Therapy, April 10, 1999, pp. 965-76, Vol. 10, no. 6.	
		Partial European Search Report, EP 99 22 4201, dated July 10, 2000.	

Examiner
Signature*[Signature]*Date
Considered

8/28/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.